Recently, antibacterial drugs against ESBL-producing Gram-negative bacteria accounted for ∼15% (2 out of 13) of all antibacterial drugs undergoing development in Phase II trials or later ...
Background: Infections caused by extended-spectrum β-lactamase (ESBL)–producing gram-negative organisms are a growing concern in hospitalized patients. Traditionally, these infections can be ...